Neuroscience
10 articles on Neuroscience, written by Shotlee and medically reviewed for clinical accuracy.
GLP-1s and Alzheimer's: Hope, Hype, and the Science of Prevention
GLP-1 receptor agonists are showing promise for brain health by reducing inflammation, but experts caution that using these powerful medications solely for dementia prevention is premature, especially given mixed clinical trial results.
6 min read
Beyond Appetite: How GLP-1 Drugs May Be Rewiring the Human Brain
GLP-1 receptor agonists, initially celebrated for revolutionizing diabetes and weight management, are now at the center of an unplanned, massive neuroscience experiment. Emerging data suggests these powerful medications are doing more than just regulating metabolism; they appear to be structurally and functionally altering key brain systems.
7 min read
Semaglutide Plateaus: New Brain Discovery Could Boost Weight Loss Results
New research from the NIH reveals how semaglutide signaling in the brain affects weight loss plateaus, offering hope for improved efficacy and dosing strategies.
7 min read
GLP-1 Drugs for Alcohol Use Disorder: The Future of Addiction Treatment?
GLP-1 receptor agonists, widely known for their efficacy in weight management and type 2 diabetes, are showing remarkable promise in addressing Alcohol Use Disorder (AUD). Emerging research suggests these injectable therapies may fundamentally alter the brain's reward pathways, offering a novel pharmaceutical path for those struggling with heavy drinking.
6 min read
Eli Lilly 150 Years: AI, GLP-1 Advances & Future of Weight Loss
Eli Lilly celebrates 150 years with a focus on AI-driven manufacturing, new GLP-1 oral therapies, and expanded neuroscience research, signaling a major shift in pharmaceutical innovation.
8 min read
AI Startup Acquires Parkinson's Cell Therapy from Ozempic Maker
Mark Zuckerberg-backed AI startup Cellular Intelligence has acquired global rights to STEM-PD, an experimental Parkinson's disease cell therapy developed by Novo Nordisk, the pharmaceutical giant behind Ozempic and Wegovy. This strategic move signals a new era for AI in accelerating complex therapeutic development.
7 min read
GLP-1 Drugs: New Insights into How They Suppress Cravings
A groundbreaking NIH-funded study reveals that emerging GLP-1 weight-loss drugs, including oral options like orforglipron, work by targeting a specific brain reward pathway, distinct from their appetite-suppressing effects. This discovery opens new avenues for understanding and treating conditions beyond weight management.
6 min read
Antimicrobial Peptides: A New Link to Neurodegenerative and Amyloid Diseases
Discover the groundbreaking research linking antimicrobial peptides (AMPs) to neurodegenerative and amyloid diseases. This article delves into the shared mechanisms, bidirectional feedback loops, and potential new therapeutic strategies emerging from this exciting field.
8 min read
Semax Peptide: Research on Neuroprotection, Inflammation, and Vascular Effects
Semax, a synthetic heptapeptide, has demonstrated neuroregulatory, neuroprotective, and immunomodulating properties in various research models. This article examines its biochemical characteristics, possible effects on gene expression, interactions with neurotransmitter systems, vascular modulation, metal binding, and utility in ischemia-reperfusion injury studies.
5 min read
Brain Scientists Aim to Develop Weight-Loss Medications Without Nausea
Scientists are striving to develop weight-loss drugs that don't cause nausea, a common side effect of medications like Wegovy and Zepbound. Research is focused on targeting specific brain regions to suppress appetite effectively without triggering nausea or other adverse effects.
4 min read